Feature ARIAD hopes to launch second oncology drug in early 2017 By Len Zehr ARIAD Pharmaceuticals (NASDAQ:ARIA) is hoping to receive FDA approval to commercialize in early 2017 its second orphan oncology product, brigatinib, for the treatment of certain genetic forms of non-small... May 17, 2016